Application
| WB, ICC |
---|---|
Primary Accession | Q9Y484 |
Other Accession | NP_001025067.1 |
Host | Rabbit |
Reactivity | Human, Rat |
Clonality | Polyclonal |
Description | Rabbit Anti-Human WDR45 Polyclonal |
Target/Specificity | Detects ~40 kDa. |
Other Names | WIPI4 Antibody, WDR45 Antibody, WDRX1 Antibody, WD repeat domain phosphoinositide-interacting protein 4 Antibody, WIPI-4 Antibody, WDRXI4 Antibody, WD repeat-containing protein 45 Antibody, ORF Names: Antibody, JM5 Antibody, |
Immunogen | Synthetic peptide from the C-terminal of Human WIPI4 (aa. 312-322) |
Purification | Peptide Affinity Purified |
Storage | -20ºC |
Storage Buffer | PBS, 50% glycerol, 0.09% sodium azide |
Shipping Temperature | Blue Ice or 4ºC |
Certificate of Analysis | A 1:1000 dilution of SPC-651 was sufficient for detection of WIPI4 in 15 µg of Human HeLa Cell Lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@clinisciences.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
WIPI-4 is a 360 amino acid protein containing three WD repeats. Existing as three alternatively spliced isoforms, WIPI-4 is ubiquitously expressed but found at highest levels in heart and skeletal muscle. WD repeat proteins are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. Diseases associated with this gene include neurodegeneration with brain iron accululation 5 and 4.
References
1. http://www.genecards.org/cgi-bin/carddisp.pl?gene=WDR45 2. Strausberg R.L., et al. (2002) Proc Natl Acad Sci U S A. 99(26): 16899–16903.
3. Haack T.B., et al. (2012) Am J Hum Genet. 91(6): 1144–1149.